anti- SOCS1 antibody

Background

SOCS1 is a critical negative regulator of cytokine signaling pathways, particularly those mediated by the Janus kinase/signal transducer and activator of transcription (JAK/STAT) system. It functions by directly binding to JAKs through its SH2 domain and targeting them for proteasomal degradation via its SOCS box, which recruits components of the ubiquitin-proteasome machinery. SOCS1 regulates immune responses by preventing excessive cytokine signaling, particularly in interferon-γ, IL-6, and IL-4 pathways, ensuring proper immune homeostasis and inflammation control. It is highly expressed in immune cells, including T cells, macrophages, and dendritic cells, where it regulates processes like cytokine sensitivity, inflammation, and T-cell activation. Dysregulation of SOCS1 contributes to autoimmune diseases, chronic inflammation, and cancer due to hyperactivation of cytokine signaling. Knockout studies reveal severe inflammatory responses, lymphocyte activation, and neonatal lethality, underscoring its essential role in immune regulation and cytokine signaling balance.